Are advocacy organizations influenced by funding from pharmaceutical companies?

A new commentary posted today on the Medscape web site addresses financial support for the activities of patient advocacy organizations by biopharmaceutical companies. … READ MORE …

Can a new logistical approach radically change surgical options for patients?

One of the things we have been asked multiple times over the years is “What does it cost to have” a radical prostatectomy, or a penile implant, or some other prostate cancer-related procedure. Usually, we have had some idea, but it can be near to impossible to get precise, total costs for such procedures — even from your local hospital. … READ MORE …

Lack of transparency re public “input” to USPSTF is rather sad

According to a new article by Andy Pollack on the New York Times Health blog just before 1:00 p.m. EST today, the U.S. Preventive Services Task Force (USPSTF) has managed to add to public confusion about its process for what was originally described as public “comment” on current draft recommendations (regarding screening tests for prostate and ovarian cancer and other disorders). … READ MORE …

Transparency and the US health care system

If you’ve recently noticed a 430+ percent increase in your bill for a single shot of leuprolide acetate (to more than $11,000), just click here for the explanation. Oh, sorry, no one can actually give you a coherent explanation (well, not if you got treated at a specific facility in Scottsdale, AZ).